Intuitive Surgical TodayISRGIntuitive Surgical$461.64 +6.63 (+1.46%) 52-Week Range$254.85▼$468.78P/E Ratio83.33Price Target$438.74Add to WatchlistIntuitive Surgical’s NASDAQ: ISRG stock bucked the broad-market selloff because of its operational quality, performance, outlook, and balance sheet, which has absolutely nothing wrong with it. The B/S highlights for Q2 include a 490 basis point increase in cash and securities and the net cash position. The net cash position is truly amazing because this company ha ...

After reaching an important support level, Intuitive Surgical, Inc. (ISRG) could be a good stock pick from a technical perspective. ISRG surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.A well-liked tool among traders, the 20-day simple moving average offers a look back at a stock's price over a 20-day period. This is very beneficial to short-term traders, as it smooths out short-term price trends and gives more trend reversal signals than longer-term moving averages. ...

Core Viewpoint - Intuitive Surgical, Inc. (ISRG) shows potential as a strong stock pick due to its recent technical performance and positive earnings estimate revisions [1][2] Technical Analysis - ISRG has surpassed resistance at the 50-day moving average, indicating a short-term bullish trend [1] - The stock has gained 5.2% over the past four weeks, reflecting positive momentum [1] Earnings Estimates - No earnings estimate for ISRG has decreased in the past two months, while two estimates have increased, suggesting a favorable outlook [1] - The consensus estimate for ISRG has also risen, reinforcing the positive sentiment around the stock [1]

SHANGHAI, CHINA - NOVEMBER 06 2022: The Da Vinci Surgical System, manufactured by Intuitive ... [+] Surgical, demonstrate its capabilities at the China International Import Expo in Shanghai, China Sunday, Nov. 06, 2022. (Photo credit should read XU CONGJUN / Feature China/Future Publishing via Getty Images)Future Publishing via Getty ImagesIntuitive Surgical (NASDAQ: ISRG) recently reported its Q2 results, with revenues matching and earnings exceeding our estimates. The company reported revenue of $2.0 bill ...

Market Overview - The Dow Jones Industrial Average, S&P 500, and Nasdaq Composite have gained 23%, 44%, and 71% respectively since the beginning of 2023, reaching all-time highs [1] - Historical patterns indicate that stock market corrections are a natural part of the investing cycle, with two predictive metrics suggesting a potential downturn for major indexes [1] Economic Indicators - The U.S. M2 money supply has declined by 3.49% since its peak in April 2022, marking the first significant drop since the Great Depression [4] - Previous instances of M2 declining by at least 2% on a year-over-year basis have coincided with economic depressions and high unemployment rates [4] - A rebound in M2 has been observed, but the current decline suggests potential pressure on discretionary spending [4] Valuation Metrics - The S&P 500's Shiller P/E ratio is currently at 35.76, significantly above the historical average of 17.14, indicating overvaluation [6][7] - Historical data shows that when the Shiller P/E has surpassed 30, the S&P 500 and Dow Jones have experienced losses ranging from 20% to 89% [6][7] Company-Specific Actions - Intuitive Surgical has been sold due to its high valuation, trading at approximately 60 times forward-year earnings despite solid operational performance [9][10] - Vertex Pharmaceuticals was also sold, as it is trading at a valuation of 12 times current-year sales and 27 times forward-year earnings, which fully values its growth prospects [11][12] - ExxonMobil was divested due to concerns over cyclical demand weakness and its high price-to-book value of 2.6, which is at a decade-high [13][14]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-30713 Intuitive Surgical, Inc. (Exact name of Registrant as specified in its Charter) Delaware 77-0416458 (State or Other Jurisdi ...

Key TakeawaysIntuitive Surgical exceeded profit and sales for the second quarter on strong demand for its da Vinci robotic surgical device.Procedures using da Vince jumped 17%, and the company placed 341 in medical facilities during the quarter.Intuitive Surgical noted that more people are having medical procedures that they had delayed during the COVID-19 pandemic. Intuitive Surgical (ISRG) shares traded at an all-time high Friday after the maker of robotic medical devices posted better-than-expected secon ...

Loading...Loading...Intuitive Surgical Inc. ISRG stock is trading higher on Friday after the robotic-assisted surgery company reported second-quarter earnings that were better than expected.William Blair writes, “All this comes in spite of several headwinds—China macro/anticorruption efforts, South Korea physician strikes, worsening bariatric volumes, and a somewhat strained supply chain—emphasizing the underlying momentum of the business and pointing to upside potential as these headwinds stabilize/improve ...

Earnings Performance - Adjusted EPS for Q2 2024 was $1.78, beating the Zacks Consensus Estimate by 16.3% and showing a 25.4% YoY improvement [1] - GAAP EPS for the quarter was $1.46, up 23.7% YoY [1] Revenue Performance - Q2 2024 revenues reached $2.01 billion, a 14% YoY increase, beating the Zacks Consensus Estimate by 2% [2] - On a constant currency basis, revenues grew 15% YoY [2] - Revenue growth was driven by increased da Vinci procedure volume and higher system installations [2] Segment Performance Instruments & Accessories - Segment revenues totaled $1.24 billion, a 16% YoY increase [3] - Growth was driven by a 17% increase in da Vinci procedure volume and 82% growth in Ion procedures [3] - Higher pricing for procedures also contributed to growth, partially offset by unfavorable customer buying patterns [3] Systems - Segment revenues reached $448 million, a 14% YoY increase [4] - The company shipped 341 da Vinci Surgical Systems, up from 331 in the prior-year quarter [4] - 70 da Vinci 5 systems were placed in Q2, following FDA approval in March [4] Services - Segment revenues amounted to $630.8 million, a 10.6% YoY increase [4] Margins - Adjusted gross profit was $14.1 billion, a 16.9% YoY increase, with gross margin at 70%, up 150 bps YoY [5] - Selling, general and administrative expenses totaled $525.3 million, up 13.1% YoY [5] - Research and development expenses totaled $280.1 million, up 14.6% YoY [5] - Adjusted operating income reached $754.1 million, a 22% YoY increase, with operating margin at 37.5%, up 230 bps YoY [5] Financial Position - Cash, cash equivalents, and investments totaled $7.68 billion at the end of Q2, up from $7.32 billion in the previous quarter [6] - Total assets increased to $16.65 billion from $15.83 billion in the prior quarter [6] Market Performance - Shares of Intuitive Surgical rose 6.7% in after-hours trading on June 18 [7] - Year-to-date, shares have risen 31.8%, outperforming the industry's 5.2% gain and the S&P 500's 16.1% gain [8] Industry Comparison - Globus Medical (GMED) has a Zacks Rank 1, with shares rising 35% year-to-date and an estimated long-term growth rate of 12.7% [9] - Hologic (HOLX) has a Zacks Rank 2, with shares rising 8.7% year-to-date and an estimated long-term growth rate of 7.4% [9] - Masimo (MASI) has a Zacks Rank 2, with shares losing 8.3% year-to-date and an estimated growth rate of 9.3% for 2025 [10]

Automation advancements have been incredible, putting the spotlight on the robotics sector as a whole. Indeed, the rise of artificial intelligence has boosted robotics use in manufacturing, healthcare, and e-commerce. This combination has the potential to revolutionize business processes and create vast new possibilities. Many companies invest billions in robotics, and one good example is Tesla (NASDAQ:TSLA).In a recent event, Elon Musk emphasized the untapped economic potential of humanoid robots. He also ...